CA3137095A1 - Bicyclic peptide ligands specific for ox40 - Google Patents
Bicyclic peptide ligands specific for ox40Info
- Publication number
- CA3137095A1 CA3137095A1 CA3137095A CA3137095A CA3137095A1 CA 3137095 A1 CA3137095 A1 CA 3137095A1 CA 3137095 A CA3137095 A CA 3137095A CA 3137095 A CA3137095 A CA 3137095A CA 3137095 A1 CA3137095 A1 CA 3137095A1
- Authority
- CA
- Canada
- Prior art keywords
- seq
- referred
- peptide
- amino acids
- loop sequences
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/50—Cyclic peptides containing at least one abnormal peptide link
- C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
- C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/50—Cyclic peptides containing at least one abnormal peptide link
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962845473P | 2019-05-09 | 2019-05-09 | |
| US62/845,473 | 2019-05-09 | ||
| PCT/GB2020/051144 WO2020225577A1 (en) | 2019-05-09 | 2020-05-11 | Bicyclic peptide ligands specific for ox40 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3137095A1 true CA3137095A1 (en) | 2020-11-12 |
Family
ID=70847426
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3137095A Pending CA3137095A1 (en) | 2019-05-09 | 2020-05-11 | Bicyclic peptide ligands specific for ox40 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US11613560B2 (https=) |
| EP (1) | EP3965827A1 (https=) |
| JP (1) | JP2022532134A (https=) |
| KR (1) | KR20220007098A (https=) |
| CN (1) | CN113811541A (https=) |
| AU (1) | AU2020269506A1 (https=) |
| BR (1) | BR112021022315A2 (https=) |
| CA (1) | CA3137095A1 (https=) |
| IL (1) | IL287881A (https=) |
| MX (1) | MX2021013669A (https=) |
| SG (1) | SG11202111606TA (https=) |
| WO (1) | WO2020225577A1 (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6882978B2 (ja) | 2014-10-29 | 2021-06-02 | バイスクルアールディー・リミテッド | Ｍｔ１−ｍｍｐに特異的な二環性ペプチドリガンド |
| JP7301757B2 (ja) | 2017-06-26 | 2023-07-03 | バイスクルアールディー・リミテッド | 検出可能部分を持つ二環式ペプチドリガンドおよびその使用 |
| CN111183147B (zh) | 2017-08-04 | 2024-07-05 | 拜斯科技术开发有限公司 | Cd137特异性的双环肽配体 |
| TWI825046B (zh) | 2017-12-19 | 2023-12-11 | 英商拜西可泰克斯有限公司 | Epha2特用之雙環胜肽配位基 |
| JP2021514953A (ja) | 2018-02-23 | 2021-06-17 | バイスクルテクス・リミテッド | 多量体二環式ペプチドリガンド |
| IL279489B2 (en) | 2018-06-22 | 2025-10-01 | Bicycletx Ltd | Bicyclic peptide ligands specific for nectin-4, a drug conjugate containing the peptide ligands and a pharmaceutical composition containing the drug conjugate |
| GB201810316D0 (en) | 2018-06-22 | 2018-08-08 | Bicyclerd Ltd | Peptide ligands for binding to EphA2 |
| GB201820325D0 (en) | 2018-12-13 | 2019-01-30 | Bicyclerd Ltd | Bicyclic peptide ligands specific for psma |
| GB201820288D0 (en) | 2018-12-13 | 2019-01-30 | Bicycle Tx Ltd | Bicycle peptide ligaands specific for MT1-MMP |
| GB201820295D0 (en) | 2018-12-13 | 2019-01-30 | Bicyclerd Ltd | Bicyclic peptide ligands specific for MT1-MMP |
| US12551567B2 (en) | 2018-12-21 | 2026-02-17 | Bicyclerd Limited | Bicyclic peptide ligands specific for PD-L1 |
| JP2022514618A (ja) | 2018-12-21 | 2022-02-14 | バイスクルテクス・リミテッド | Ｐｄ－ｌ１に特異的な二環式ペプチドリガンド |
| GB201900529D0 (en) | 2019-01-15 | 2019-03-06 | Bicycletx Ltd | Bicyclic peptide ligands specific for CD38 |
| KR20220007098A (ko) | 2019-05-09 | 2022-01-18 | 바이사이클티엑스 리미티드 | Ox40에 특이적인 이환식 펩티드 리간드 |
| TWI860386B (zh) | 2019-07-30 | 2024-11-01 | 英商拜西可泰克斯有限公司 | 異質雙環肽複合物 |
| ES3033517T3 (en) * | 2019-10-03 | 2025-08-05 | Bicycletx Ltd | Heterotandem bicyclic peptide complexes |
| IL300248A (en) | 2020-08-03 | 2023-03-01 | Bicycletx Ltd | peptide-based linkers |
| KR20230141794A (ko) * | 2021-01-08 | 2023-10-10 | 바이사이클티엑스 리미티드 | 헤테로탠덤 바이사이클릭 펩티드 복합체 |
| MX2024003876A (es) | 2021-09-29 | 2024-04-19 | Conjustar Zhuhai Biologics Co Ltd | Conjugado farmaco-polipeptido triciclico y sus aplicaciones. |
| CN114933638B (zh) * | 2022-05-12 | 2024-07-26 | 厦门大学 | 特异性靶向cd28的多元环肽配体框架 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6927203B1 (en) | 1999-08-17 | 2005-08-09 | Purdue Research Foundation | Treatment of metastatic disease |
| EP1452868A2 (en) | 2003-02-27 | 2004-09-01 | Pepscan Systems B.V. | Method for selecting a candidate drug compound |
| AU2009211253B2 (en) | 2008-02-05 | 2014-11-06 | Bicyclerd Limited | Methods and compositions |
| GB0913775D0 (en) | 2009-08-06 | 2009-09-16 | Medical Res Council | Multispecific peptides |
| WO2012057624A1 (en) | 2010-10-25 | 2012-05-03 | Pepscan Systems B.V. | Novel bicyclic peptide mimetics |
| AU2012369202A1 (en) * | 2012-02-06 | 2014-09-25 | Providence Health & Services - Oregon | Cancer treatment and monitoring methods using OX40 agonists |
| ES2705068T3 (es) | 2013-05-23 | 2019-03-21 | Ohio State Innovation Foundation | Síntesis química y cribado de bibliotecas de péptidos bicíclicos |
| EP3613426A1 (en) | 2014-05-21 | 2020-02-26 | Entrada Therapeutics, Inc. | Cell penetrating peptides and methods of making and using thereof |
| JP6882978B2 (ja) | 2014-10-29 | 2021-06-02 | バイスクルアールディー・リミテッド | Ｍｔ１−ｍｍｐに特異的な二環性ペプチドリガンド |
| IL274572B2 (en) * | 2015-07-16 | 2024-01-01 | Biolinerx Ltd | Compositions and methods for treating cancer |
| JP2019513371A (ja) | 2016-04-01 | 2019-05-30 | アビディティー バイオサイエンシーズ エルエルシー | 核酸ポリペプチド組成物とその使用 |
| AU2017252233A1 (en) | 2016-04-22 | 2018-11-15 | Alligator Bioscience Ab | Novel bispecific polypeptides against CD137 |
| GB201607827D0 (en) | 2016-05-04 | 2016-06-15 | Bicycle Therapeutics Ltd | Bicyclic peptide-toxin conjugates specific for MT1-MMP |
| WO2018115203A1 (en) | 2016-12-23 | 2018-06-28 | Bicyclerd Limited | Peptide derivatives having novel linkage structures |
| IL268836B2 (en) | 2017-02-24 | 2024-04-01 | Macrogenics Inc | Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof |
| CN111183147B (zh) | 2017-08-04 | 2024-07-05 | 拜斯科技术开发有限公司 | Cd137特异性的双环肽配体 |
| GB201721265D0 (en) | 2017-12-19 | 2018-01-31 | Bicyclerd Ltd | Bicyclic peptide ligands specific for EphA2 |
| TWI825046B (zh) | 2017-12-19 | 2023-12-11 | 英商拜西可泰克斯有限公司 | Epha2特用之雙環胜肽配位基 |
| JP2021514953A (ja) | 2018-02-23 | 2021-06-17 | バイスクルテクス・リミテッド | 多量体二環式ペプチドリガンド |
| JP7551500B2 (ja) | 2018-04-04 | 2024-09-17 | バイスクルテクス・リミテッド | ヘテロタンデム二環式ペプチド複合体 |
| IL279489B2 (en) | 2018-06-22 | 2025-10-01 | Bicycletx Ltd | Bicyclic peptide ligands specific for nectin-4, a drug conjugate containing the peptide ligands and a pharmaceutical composition containing the drug conjugate |
| GB201810316D0 (en) | 2018-06-22 | 2018-08-08 | Bicyclerd Ltd | Peptide ligands for binding to EphA2 |
| WO2020084305A1 (en) | 2018-10-23 | 2020-04-30 | Bicycletx Limited | Bicyclic peptide ligands and uses thereof |
| JP2022514618A (ja) | 2018-12-21 | 2022-02-14 | バイスクルテクス・リミテッド | Ｐｄ－ｌ１に特異的な二環式ペプチドリガンド |
| US20220184222A1 (en) | 2019-04-02 | 2022-06-16 | Bicycletx Limited | Bicycle toxin conjugates and uses thereof |
| KR20220007098A (ko) | 2019-05-09 | 2022-01-18 | 바이사이클티엑스 리미티드 | Ox40에 특이적인 이환식 펩티드 리간드 |
| TWI860386B (zh) | 2019-07-30 | 2024-11-01 | 英商拜西可泰克斯有限公司 | 異質雙環肽複合物 |
| ES3033517T3 (en) | 2019-10-03 | 2025-08-05 | Bicycletx Ltd | Heterotandem bicyclic peptide complexes |
| CN114760988A (zh) | 2019-11-27 | 2022-07-15 | 拜斯科技术开发有限公司 | 对EphA2具有特异性的双环肽配体和其用途 |
| EP4165414A1 (en) | 2020-06-12 | 2023-04-19 | BicycleTX Limited | Treatment of diseases characterized by overexpression of erythropoietin-producing hepatocellular receptor a2 (epha2) |
-
2020
- 2020-05-11 KR KR1020217039675A patent/KR20220007098A/ko not_active Ceased
- 2020-05-11 AU AU2020269506A patent/AU2020269506A1/en not_active Abandoned
- 2020-05-11 SG SG11202111606TA patent/SG11202111606TA/en unknown
- 2020-05-11 MX MX2021013669A patent/MX2021013669A/es unknown
- 2020-05-11 WO PCT/GB2020/051144 patent/WO2020225577A1/en not_active Ceased
- 2020-05-11 CA CA3137095A patent/CA3137095A1/en active Pending
- 2020-05-11 BR BR112021022315A patent/BR112021022315A2/pt not_active IP Right Cessation
- 2020-05-11 CN CN202080033959.9A patent/CN113811541A/zh active Pending
- 2020-05-11 JP JP2021566259A patent/JP2022532134A/ja active Pending
- 2020-05-11 US US16/872,097 patent/US11613560B2/en active Active
- 2020-05-11 EP EP20728128.8A patent/EP3965827A1/en not_active Withdrawn
-
2021
- 2021-11-07 IL IL287881A patent/IL287881A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022532134A (ja) | 2022-07-13 |
| US11613560B2 (en) | 2023-03-28 |
| KR20220007098A (ko) | 2022-01-18 |
| WO2020225577A1 (en) | 2020-11-12 |
| IL287881A (en) | 2022-01-01 |
| CN113811541A (zh) | 2021-12-17 |
| BR112021022315A2 (pt) | 2021-12-28 |
| SG11202111606TA (en) | 2021-11-29 |
| MX2021013669A (es) | 2021-12-10 |
| EP3965827A1 (en) | 2022-03-16 |
| AU2020269506A1 (en) | 2022-01-06 |
| US20200354406A1 (en) | 2020-11-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11613560B2 (en) | Bicyclic peptide ligands specific for OX40 | |
| AU2019247795B2 (en) | Heterotandem bicyclic peptide complexes | |
| ES3033517T3 (en) | Heterotandem bicyclic peptide complexes | |
| AU2020322193B2 (en) | Heterotandem bicyclic peptide complexes | |
| CN113543813B (zh) | Cd38特异性的双环肽配体 | |
| JP2024023291A (ja) | 多量体二環式ペプチドリガンド | |
| CN114787197A (zh) | 修饰的多聚双环肽配体 | |
| EP3911743A1 (en) | Bicyclic peptide ligands specific for caix | |
| EP3911665A1 (en) | Bicyclic peptide ligands specific for caix | |
| WO2020120980A1 (en) | Bicyclic peptide ligands specific for psma | |
| HK40123165A (en) | Heterotandem bicyclic peptide complexes | |
| HK40117689B (en) | Heterotandem bicyclic peptide complexes | |
| HK40117689A (en) | Heterotandem bicyclic peptide complexes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| U13 | Renewal or maintenance fee not paid |
Free format text: ST27 STATUS EVENT CODE: N-1-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE Effective date: 20241113 |
|
| N11 | Application terminated |
Free format text: ST27 STATUS EVENT CODE: T-6-6-N10-N11-N106 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION NOT REINSTATED BY DEADLINE Effective date: 20251113 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20251229 |
|
| U13 | Renewal or maintenance fee not paid |
Free format text: ST27 STATUS EVENT CODE: N-6-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE Effective date: 20260221 |